Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADG126 Monotherapy and Combinations in Advanced Solid Tumors
NCT04645069Phase 2Completed
- Sponsor
- Adagene
- Start
- Mar 2021
- Primary completion
- Jan 2024
- Modality
- Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of muzastotug in solid tumor (advanced stage), sponsored by Adagene. Started Mar 2021; status: completed.
02
Drugs
muzastotug
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT04645069.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04645069.